Avascular Necrosis News and Research

RSS
FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Cartilage graft can stimulate bone regeneration

Cartilage graft can stimulate bone regeneration

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

FDA panel votes against Amgen’s Xgeva in prostate cancer

FDA panel votes against Amgen’s Xgeva in prostate cancer

FDA reviews Amgen’s prostate cancer drug Xgeva

FDA reviews Amgen’s prostate cancer drug Xgeva

New discovery paves way for genetic screening test

New discovery paves way for genetic screening test

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

Adjuvant zoledronic acid shows promise against ER-positive premenopausal breast cancer

FDA reviews safety issues of bisphosphonates for osteoporosis

FDA reviews safety issues of bisphosphonates for osteoporosis

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Oral bisphosphonates outweigh the risk associated with jaw disease

Oral bisphosphonates outweigh the risk associated with jaw disease

JDR releases research report on Osteonecrosis of the jaw

JDR releases research report on Osteonecrosis of the jaw

FDA stops pain drug trial over safety concerns

FDA stops pain drug trial over safety concerns

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases